Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ITK | Q08881 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585273 | 0.84 | MAOA (0.34) | SMN1; SMN2CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL1854878 | 0.84 | PDE2A (0.37) | SMN1; SMN2CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL2325507 | 0.84 | CYP1A2 (0.32) | SMN1; SMN2CYP1A2CYP19A1CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL584375 | 0.83 | CHRNB2 (0.33) | SMN1; SMN2CYP1A2CYP19A1CYP2C9CYP2C19 | |
| Dimethylamine SCHEMBL1861764 | 0.82 | KDM4E (0.38) | SMN1; SMN2CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL4745597 | 0.82 | GRM5 (0.35) | CYP1A2CYP2C19 | |
| SCHEMBL2202844 | 0.80 | TSHR (0.37) | SMN1; SMN2CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL585529 | 0.79 | CLK4 (0.39) | SMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| Dimethylamine SCHEMBL1859717 | 0.75 | DHODH (0.33) | — | |
| SCHEMBL2360345 | 0.74 | CYP1A2 (0.32) | SMN1; SMN2CYP1A2CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558616-B2 | MESO-SUBSTITUTED PORPHYRINS | MOLTENI & C (IT) | 2011-08-24 | — | — | EP | claimed |
| JP-4751068-B2 | — | — | 2011-08-17 | — | — | JP | claimed |
| EP-1558616-B1 | MESO-SUBSTITUTED PORPHYRINS | MOLTENI & C (IT) | 2008-02-27 | — | — | EP | claimed |
| US-20060040914-A1 | Meso-substituted porphyrins | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA DI ESERCIZIO S.P.A. (IT) | 2006-02-23 | — | — | US | claimed |
| EP-1558616-A2 | MESO-SUBSTITUTED PORPHYRINS | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO SOCIETA' PER AZIONI (IT) | 2005-08-03 | — | — | EP | claimed |
| WO-2004035590-A2 | MESO-SUBSTITUTED PORPHYRINS | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA DI ESERCIZIO S.P.A (IT) | 2004-04-29 | — | — | WO | claimed |
| US-8288528-B2 | Meso-substituted porphyrins | L. Molteni & C. Dei Fratelli Alitti—Società di Esercizio S.p.A. (IT) | 2012-10-16 | — | — | US | disclosed |
| EP-1558616-B2 | MESO-SUBSTITUTED PORPHYRINS | MOLTENI & C (IT) | 2011-08-24 | — | — | EP | disclosed |
| US-7947674-B2 | Meso-substituted porphyrins | L. Molteni & C. Dei Fratelli Alitti (IT) | 2011-05-24 | — | — | US | disclosed |
| US-20110112464-A1 | MESO-SUBSTITUTED PORPHYRINS | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA DI ESERCIZIO S.P.A. (IT) | 2011-05-12 | — | — | US | disclosed |
| EP-1558616-B1 | MESO-SUBSTITUTED PORPHYRINS | MOLTENI & C (IT) | 2008-02-27 | — | — | EP | disclosed |
| US-20060040914-A1 | Meso-substituted porphyrins | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA DI ESERCIZIO S.P.A. (IT) | 2006-02-23 | — | — | US | disclosed |
| EP-1558616-A2 | MESO-SUBSTITUTED PORPHYRINS | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO SOCIETA' PER AZIONI (IT) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004035590-A2 | MESO-SUBSTITUTED PORPHYRINS | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA DI ESERCIZIO S.P.A (IT) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040914-A1 | Meso-substituted porphyrins | PPOX, PPIF, ALAD | FFAR1 3955/4885SMN1; SMN2 2547/4885FFAR4 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.